OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS

Equity Capital Raises

Equity Transaction Chart

Viridian publishes weekly data on equity capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing equity (public/private, state/country location), deal size, deal structure, pricing, share information, deal implied valuation, and warrant information.

Week ended 03/01/2024

Week ended 03/01/2024

This Section is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.

Equity Commentary

Viridian publishes weekly insights on equity capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful equity transactions of that week, and commentary on market conditions, equity deal structures and investor groups.

Week ended 03/01/2024

  • The Week’s Closed Equity Deals
    • On February 27, 2024, Elevated Signals (Private), a Canadian pioneer in manufacturing software for cannabis and controlled environment agriculture, completed a $5.9M Series A funding round.
      • The round was led by Yaletown Partners, with participation from Third Kind Venture Capital, WGD Capital, Colin Harris, Raiven Capital, and Pareto Holdings.
      • Funds will be used to continue the firm’s expansion into a growing list of business types, including food, energy health, and others.
  • On February 26, 2024, Revive Therapeutics Ltd. (RVV: CSE) (RVVTF: OTCQB), a Psychedelics sector company exploring the use of Bucillamine for the potential treatment of public health emergencies, as well as advancing the development of Psilocybin based therapeutics, closed a private placement of 33.9M units at $0.0259 per unit, for gross proceeds of $0.88M.
    • Each unit consisted of one share and ½ warrant with an exercise price of $.0370 (42.9% premium) and a three-year expiration.
    • The ½ share of warrants at a reasonably high 43% premium restricts the warrant value to $.002 per unit. The net share price of $.024 is an 18.95% discount to the pre-announcement price.
    • Revive will need additional financing in relatively little time, as evidenced by its proforma free cash flow adjusted current ratio of .14x. The company has a cash burn rate of approximately $2.6M per quarter.
    • The transaction implies a market cap of $9.5M and an enterprise value of $8.11M.
    • The proceeds will fund clinical work on long COVID, possible repayment of payables, and general corporate purposes.

Public vs. Private Raises: 

  • Revive Therapeutics, this week’s only public capital raiser, trades on the CSE in Canada and the OTCQB in the U.S.

Equity vs. Debt Cap Raises: 

  • Equity accounted for all of this week’s capital raises.

Week ended 03/01/2024

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more. 

Weekly Valuation Tracker

Viridian highlights a specific industry sector and provides a deep dive into valuation metrics and comparable company valuations for public companies operating in that sector.  The Weekly Valuation Tracker provides proprietary, actionable valuation data.

This week’s valuation tracker focuses on the 7 U.S. MSOs with market cap over $500M in the Viridian Value Tracker database in gauge the valuation impact of the 2nd earnings that have been released so far, Green Thumb (GTII: CSE), Curaleaf (CURA: CSE), and Trulieve.   

This Chart is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more. 

This Chart is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.